|
T15108 |
DG-041
|
|
Prostaglandin Receptor
|
|
DG-041 is an antagonist of high-affinity EP3 receptor (IC50s: 4.6 nM and 8.1 nM in the binding and FLIPR assay, respectively). DG-041 inhibits PGE2 facilitation of platelet aggregation and has the blood-brain barrier per... |
|
T9920 |
Evolocumab
|
|
Others
|
|
Evolocumab is a human IgG2 monoclonal antibody that binds to human PCSK9 Proprotein Convertase Subtilisin Kexin Type 9). |
|
T0686 |
Orlistat
|
Ro-18-0647,Tetrahydrolipstatin |
Apoptosis
,
Others
,
Fatty Acid Synthase
|
|
Orlistat (Tetrahydrolipstatin) is an Intestinal Lipase Inhibitor. The mechanism of action of orlistat is as a Lipase Inhibitor. |
|
T23550 |
YM-750
|
YM 750 |
Acyltransferase
|
|
YM-750 is a potent inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT), with an IC50 value of 0.18 μM. ACAT is an enzyme that catalyzes the conversion of cholesterol and long-chain fatty-acyl-coenzyme A into cholest... |
|
T1781 |
GW9508
|
GW 9508 |
GPR
,
Potassium Channel
|
|
GW9508(GW 9508) is a potent and selective agonist for FFA1 (GPR40), stimulates insulin secretion in a glucose-sensitive manner. |
|
T15757 |
Limaprost
|
17α,20-dimethyl-δ2-PGE1,OP1206,ONO1206 |
PGE Synthase
|
|
Limaprost (17α,20-dimethyl-δ2-PGE1) is an analog of PGE1 with structural modifications intended to give it a prolonged half-life and greater potency.It is a potent and orally active vasodilator. Limaprost increases blood... |
|
T10063 |
LDL-IN-3
|
|
Antioxidant
|
|
LDL-IN-3 shows anti-atherosclerotic and antioxidant activities. |
|
T12981 |
SP-8356
|
|
Autophagy
|
|
SP-8356 is a potent, orally active inhibitor of cluster of differentiation 147 (CD147),and is an anti-inflammatory synthetic verbenone derivative, with anti-atherosclerotic effects. |
|
T30506 |
BMS-212122
|
UNII-0Z473OO6GB,BMS212122,BMS 212122 |
CETP
|
|
BMS-212122 (UNII-0Z473OO6GB) is a potent inhibitor of microsomal triglyceride transfer protein (MTP) and has shown hypolipidemic effects in animal studies.BMS-212122 significantly reduced lipid content and monocyte-deriv... |
|
T17157 |
TRAF-STOP inhibitor 6877002
|
CD40-TRAF6 inhibitor |
NF-κB
|
|
TRAF-STOP inhibitor 6877002 (CD40-TRAF6 inhibitor), is a selective inhibitor of CD40-TRAF6 interaction. TRAF-STOP 6877002 reduces leukocyte recruitment, and reduces macrophage activation; reduces macrophage proliferation... |
|
T12848 |
SB-657510
|
|
Others
,
Neurotensin Receptor
|
|
SB-657510 is a urotensin II (UII) receptor (UT) antagonist. The Ki values of UT for human, monkey, cat, rat and mouse were 61, 17, 30, 65 and 56 nM, respectively. SB-657510 plays an anti-inflammatory role by inhibiting U... |
|
T28290 |
Pactimibe
|
CS 505,CS-505,CS505,Pactimibe free base |
|
|
Pactimibe is a ACAT inhibitor. It has anti-atherosclerotic activity. |
|
T24592 |
Pamaqueside
|
CP-148,623,CP 148623,L 165313,L165313,L-165313 |
|
|
Pamaqueside is an anti-atherosclerotic agent. |
|
T32028 |
GYKI-14451 sulfate
|
GYKI14451,GYKI14,451,GYKI-14451,GYKI 14451,GYKI 14,451,GYKI-14,451 |
|
|
GYKI-14451 (LY-178207) is a synthetic thrombin tripeptide inhibitor with anti-atherosclerotic activity. |
|
T30917 |
CI 924
|
EINECS 279-174-7,CI-924,CI924 |
|
|
CI 924 is a lipid-lowering drug. CI 924 increased anti-atherosclerotic HDL and decreased VLDL at 600 mg/day. |
|
T32782 |
Lipopeptin A
|
|
|
|
Lipopeptin A is a lipoprotein subclass that is a risk factor for atherosclerotic diseases such as coronary heart disease and stroke. |
|
T33448 |
ML 10
|
ML-10,ML10 |
|
|
ML 10 is is a [18F] positron emission tomography (PET) radiotracer that accumulates in cells presenting apoptosis-specific membrane alterations. [18F]ML-10 allows for the detection of apoptotic cells located in atheroscl... |
|
T41135 |
Defensin HNP-1 human
|
|
|
|
Defensin HNP-1 human is a Human neutrophil peptides (HNPs), involved in endothelial cell dysfunction at the time of early atherosclerotic development.Defensin HNP-1 human can regulate the growth of atherosclerosis. |
|
T69456 |
Melagatran monohydrate
|
|
|
|
Melagatran monohydrate is a thrombin inhibitor. Melagatran prevents tissue factor expression in human platelet-monocyte heterotypic complexes. Melagatran reduces advanced atherosclerotic lesion size and may promote plaqu... |
|
T28429 |
PMX-53
|
PMX53,PMX 53 |
|
|
PMX-53 is a Mas-related gene 2 (MrgX2) agonist and C5aR(CD88) antagonist. PMX-53 reduces atherosclerotic lesions in a mouse model of atherosclerosis, inhibits lung metastasis in a mouse breast cancer model, inhibits C5a-... |
|
T36727 |
9(S)-HODE
|
|
|
|
9(S)-HODE is produced by the lipoxygenation of linoleic acid in both plants and animals.[1],[2] It has been detected in atherosclerotic plaques, as an esterified component of membrane phospholipids and in oxidized LDL pa... |
|
T35405 |
(±)9-HODE cholesteryl ester
|
|
|
|
(±)9-HODE cholesteryl ester was originally extracted from atherosclerotic lesions and shown to be produced by Cu2+-catalyzed oxidation of LDL. Later studies determined that 15-LO from rabbit reticulocytes and human monoc... |
|
T35404 |
(±)13-HODE cholesteryl ester
|
|
|
|
(±)13-HODE cholesteryl ester was originally extracted from atherosclerotic lesions and shown to be produced by Cu2+-catalyzed oxidation of LDL. Later studies determined that 15-LO from rabbit reticulocytes and human mono... |
|
T35853 |
9(S)-HODE cholesteryl ester
|
|
|
|
9(S)-HODE cholesteryl ester was originally extracted from atherosclerotic lesions. It remains uncertain whether the oxidized fatty acid portion of the molecule results from enzymatic lipoxygenation or from random lipid p... |
|
T35846 |
13(R)-HODE cholesteryl ester
|
|
|
|
13(R)-HODE cholesteryl ester was originally extracted from atherosclerotic lesions. It remains uncertain whether the oxidized fatty acid portion of the molecule results from enzymatic lipoxygenation or from random lipid ... |
|
T35843 |
9(R)-HODE cholesteryl ester
|
|
|
|
9(R)-HODE cholesteryl ester was originally extracted from atherosclerotic lesions. It remains uncertain whether the oxidized fatty acid portion of the molecule results from enzymatic lipoxygenation or from random lipid p... |
|
T64361 |
6-NBDG
|
|
Others
|
|
6-NBDG, a fluorescent glucose analogue, can be used as a fluorescent probe.6-NBDG can be used for monitoring glucose transport and uptake. 6-NBDG can be used as for detecting macrophage-rich atherosclerotic plaques. |
|
T78806 |
PPARδ agonist 9
|
|
PPAR
|
|
PPARδ agonist 9 (compound 21), with an EC50 of 3.6 nM, is effective in vivo, decreasing serum MCP-1 concentrations in mice and markedly reducing atherosclerotic development in the LDLr-KO model with an inhibition rate of... |
|
T21814 |
ONO 4817
|
|
|
|
ONO-4817 is a broad-spectrum matrix metalloproteinase (MMP) inhibitor that potentially mitigates atherosclerotic neointimal proliferation and atheromatous plaque progression by suppressing matrix metalloproteinases (MMPs... |
|
T71306 |
Gemfibrozil-d6
|
|
|
|
Gemfibrozil-d6 is intended for use as an internal standard for the quantification of gemfibrozil by GC- or LC-MS. Gemfibrozil is a peroxisome proliferator-activated reporter α and PPARγ agonist. In vivo, gemfibrozil redu... |
|
T36731 |
Cholesteryl Heptadecanoate
|
|
|
|
Cholesteryl heptadecanoate is a cholesterol ester (CE) formed by the condensation of cholesterol with heptadecanoic acid, a C-17 saturated fatty acid that does not occur in any natural animal or vegetable fat at high con... |
|
T35985 |
CAY10487
|
|
|
|
The early stage of atherosclerosis is characterized by the aggregation of foam cells, so called a fatty streak, in the inner arterial wall. CAY10487 inhibits formation of fatty streak lesions of the thoracic aorta in hig... |
|
T37393 |
13(S)-HpODE
|
|
|
|
13(S)-HpODE is produced by the oxidation of linoleic acid by lipoxygenase-1 (LO-1) in many plants including soybean, flaxseed, apples, and tea leaves,1,2 and by 15-LO in mammals.3 In plants, 13(S)-HpODE is the preferred ... |
|
T7072 |
Pitavastatin
|
|
|
|
Pitavastatin (NK-104) is a potent inhibitor of hydroxymethylglutaryl-CoA (HMG-CoA) reductase, effectively inhibiting cholesterol synthesis from acetic acid in HepG2 cells with an IC 50 of 5.8 nM. It also acts as an effic... |
|
T36235 |
5-Chlorouracil
|
|
|
|
5-Chlorouracil is a chlorinated derivative of the pyrimidine nucleoside base uracil . In vivo, it is converted into chlorodeoxyuridine, which is mutagenic and genotoxic.1 Uracil is chlorinated at the 5 position in a cell... |
|
T83710 |
Gastric Inhibitory Peptide (22-51) (human) TFA
|
GIP (22-51),Glucose-dependent Insulinotropic Peptide (22-51) |
|
|
Gastric inhibitory peptide (GIP) (22-51), a pro-atherogenic peptide comprised of 30 amino acids from the residues 22-51 of its precursor protein proGIP, is present in human plasma. It activates the degradation of IκB-α a... |
|
T35578 |
Phosphatidylserines (sodium salt)
|
Phosphatidylserines (sodium salt),L-α-Phosphatidylserine |
|
|
Phosphatidylserine is a naturally occurring phospholipid that comprises 2-10% of total phospholipids in mammals and is enriched in the central nervous system, particularly the retina. It is anionic and found mainly on th... |
|
T83669 |
PMX-53 TFA
|
AcPhe-[Orn-Pro-D-Cyclohexylalanine-Trp-Arg],AcF-[OPdChaWR],3D53 |
|
|
PMX-53, a macrocyclic complement 5a (C5a) peptidomimetic and C5a receptor antagonist (IC50 = 0.3 µM), effectively inhibits the C5a-induced secretion of myeloperoxidase (MPO) in isolated human polymorphonuclear leukocytes... |
